T Buclin

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi Monitoring drug therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 73:917-23. 2012
  2. ncbi Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
    Nancy Perrottet
    Microbiology Institute, University Hospital, Lausanne, Switzerland
    BMC Infect Dis 10:2. 2010
  3. ncbi [Will good clinical practice domesticate human research?]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont CHUV, Lausanne
    Rev Med Suisse 2:992-6. 2006
  4. ncbi Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 6:e18578. 2011
  5. ncbi An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients
    E Dahmane
    Division of Clinical Pharmacology and Toxicology, Department of Medecine, Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-14. 2010
  6. ncbi High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function
    F Lamoth
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 54:4360-7. 2010
  7. ncbi Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
    L A Decosterd
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ren Fail 20:311-7. 1998
  8. ncbi Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009
  9. ncbi Estimation of glomerular filtration rate by sinistrin clearance using various approaches
    T Buclin
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Ren Fail 20:267-76. 1998
  10. ncbi [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 6:128-31. 2010

Collaborators

Detail Information

Publications33

  1. ncbi Monitoring drug therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 73:917-23. 2012
    ....
  2. ncbi Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
    Nancy Perrottet
    Microbiology Institute, University Hospital, Lausanne, Switzerland
    BMC Infect Dis 10:2. 2010
    ..This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response (DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease...
  3. ncbi [Will good clinical practice domesticate human research?]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont CHUV, Lausanne
    Rev Med Suisse 2:992-6. 2006
    ..No clinical study should be planned without consideration of a series of legal requirements, which are reviewed. Concerns about their practical implications are critically assessed...
  4. ncbi Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 6:e18578. 2011
    ..We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study...
  5. ncbi An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients
    E Dahmane
    Division of Clinical Pharmacology and Toxicology, Department of Medecine, Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-14. 2010
    ....
  6. ncbi High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function
    F Lamoth
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 54:4360-7. 2010
    ..Careful adherence to normalized dosing per 100 ml/min GFR is crucial. Monitoring of plasma concentrations may contribute to preventing neurological toxicity of high-dose therapy for this life-threatening condition...
  7. ncbi Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
    L A Decosterd
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ren Fail 20:311-7. 1998
    ..87 +/- 0.13 implying unphysio-logical values (> 1) in some cases. In conclusion HPLC not only enables the simultaneous quantitation of PAH and NAc-PAH, but may also provide more accurate and precise PAH clearance measurements...
  8. ncbi Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009
    ..Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels...
  9. ncbi Estimation of glomerular filtration rate by sinistrin clearance using various approaches
    T Buclin
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Ren Fail 20:267-76. 1998
    ..D/AUC represents the most advisable approach for snapshot renal testing in subjects or patients without important renal impairment...
  10. ncbi [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 6:128-31. 2010
    ..Raised concerns of causality between insuline glargine and malignant tumors are not supported by strong evidence. Proton pump inhibitors seem to blunt clopidogrel benefit. Aliskiren can cause angioedema...
  11. ncbi [Effects of oral cannabis and dronabinol on driving capacity]
    C Giroud
    Laboratoire de toxicologie et chimie forensiques, institut universitaire de médecine légale IUML, Rue du Bugnon 21, CH 1005 Lausanne, Suisse
    Ann Pharm Fr 64:161-72. 2006
    ..The Cannabis Influence Factor (CIF) which relies on the molar ratio of active and inactive cannabinoids in blood provided a good estimate of the fitness to drive...
  12. ncbi [Risk of overtreatment: not to be neglected. The example of antiepileptic drugs]
    L E Rothuizen
    Division de pharmacologie et toxicologie cliniques, Département de médecine Hôpital Beaumont, CHUV, Lausanne
    Rev Med Suisse 2:976-80. 2006
    ..Its prevention requires the recognition of the situations and the understanding of the mechanisms leading to it. The pharmacological treatment of epilepsy exposes to such a risk and serves as an example for its detection and correction...
  13. ncbi [Trends in drug therapy]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, Lausanne
    Rev Med Suisse 2:155-9. 2006
    ..Risk-benefit assessment of drugs is a dynamic process. One must keep in mind that the data on the relationship between drugs and the clinical picture are of variable quality and that the size of the risk is often difficult to assess...
  14. ncbi [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, CHUV, 1011 Lausanne
    Rev Med Suisse 4:150-4. 2008
    ..Besides biological investigations of questionable relevance and clinical trial of inconstant efficiency towards safety outcomes, the role of pharmacovigilance notifications by practitioners remains of paramount importance...
  15. ncbi [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, 1011 Lausanne
    Rev Med Suisse 7:71-4. 2011
    ..The correct use of transdermal patches is reviewed with the example of rivastigmine. Aseptic meningitis is a rare adverse reaction of lamotrigine. An increased risk of fractures after long term use of proton pump inhibitors is suspected...
  16. ncbi Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers
    C B Eap
    Departement universitaire de psychiatrie adulte, Hôpital de Cery, Prilly, Lausanne, Switzerland
    Clin Pharmacol Ther 64:52-7. 1998
    ..It is known that CYP2E1 is involved in the activation of many low-molecular-weight toxins and carcinogens and may be involved in the development of alcohol-induced liver disease...
  17. ncbi Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir
    N Perrottet
    Division of Clinical Pharmacology and Toxicology Département de Médecine, Hôpital de Beaumont 06, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:3017-23. 2009
    ..However, GCV plasma measurement may still be helpful in specific clinical situations...
  18. ncbi Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
    C Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 57:723-7. 2001
    ....
  19. ncbi Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
    N Widmer
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Br J Clin Pharmacol 62:97-112. 2006
    ..Ideally, such an approach should take account of either circulating alpha1-acid glycoprotein concentrations or free imatinib concentrations...
  20. ncbi Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies
    F Lamoth
    Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    Antimicrob Agents Chemother 53:785-7. 2009
    ..The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day...
  21. ncbi [Antimicrobial agents and renal elimination: towards individual dosage adjustment?]
    C Willi-Robatel
    Division de pharmacologie et toxicologie cliniques, Département des laboratoires, CHUV, Lausanne
    Rev Med Suisse 8:894-900. 2012
    ..The literature has been reviewed and compared to a predictive model of the fraction of drug cleared by the kidney based on the Dettli's principle. Revised drug dosing recommendations integrating these predictive parameters are proposed...
  22. ncbi Diet acids and alkalis influence calcium retention in bone
    T Buclin
    Division of Clinical Pharmacology, University Hospital CHUV, Lausanne, Switzerland
    Osteoporos Int 12:493-9. 2001
    ..Further studies are needed to determine the clinical impact of dietary counseling for avoiding diet acids as a preventive measure against osteoporosis...
  23. ncbi Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
    N Widmer
    Division of Clinical Pharmacology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Cancer 98:1633-40. 2008
    ..Our findings represent additional arguments to further evaluate the usefulness of individualizing imatinib prescription based on a therapeutic drug monitoring programme, possibly associated with target genotype profiling of patients...
  24. ncbi [Drugs and breastfeeding: some facts to consider before deciding they are incompatible]
    A Panchaud
    Division de pharmacologie et toxicologie cliniques, CHUV, Lausanne
    Rev Med Suisse 4:540-5. 2008
    ..This article aims to review the facts needed to assess amount of drug exposure to the child and to list the few drugs associated with significant effects on the nursing infant...
  25. ncbi A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
    A Fayet
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1057-69. 2009
    ....
  26. ncbi Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist
    E Grouzmann
    Division d Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Biol Chem 272:7699-706. 1997
    ..48. Thus, to our best knowledge, T4-[NPY(33-36)]4 represents the first potent and selective Y2 antagonist...
  27. ncbi Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
    C Robatel
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Antimicrob Chemother 54:269-70. 2004
    ..The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. CONCLUSIONS: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment...
  28. ncbi Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
    C Robatel
    Division of Clinical Pharmacology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Clin Pharmacol 43:1329-40. 2003
    ..The results indicate that two different therapeutic schedules of meropenem are equally applicable to patients receiving CVVHD: either 750 mg tid or 1500 bid...
  29. ncbi Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people
    C Giroud
    Laboratoire de Toxicologie Analytique, , Lausanne, Switzerland
    Forensic Sci Int 123:159-64. 2001
    ..6 to calculate plasma concentrations from blood values. In the case of blood samples taken after death, the use of these models to assess the time of Cannabis use is not recommended...
  30. ncbi The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial
    C Mazzocato
    Division of Palliative Care, University Hospital, Lausanne, Switzerland
    Ann Oncol 10:1511-4. 1999
    ..This study was undertaken to assess the efficacy of morphine on dyspnea and its safety for ventilatory function in elderly advanced cancer patients...
  31. ncbi Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
    N Widmer
    Division de pharmacologie clinique, Laboratoire BH 18-218, , Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 803:285-92. 2004
    ..7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients...
  32. ncbi Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
    N Widmer
    Leukemia 21:1561-2; author reply 1562-4. 2007
  33. ncbi Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    C Marzolini
    Department of Medicine, University Hospital of Lausanne, Switzerland
    AIDS 15:71-5. 2001
    ..The important inter-individual variability in efavirenz levels strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment...